BR112017003486A2 - métodos para expressar uma molécula antigênica ou uma parte da mesma e gerar uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e molécula antigênica, molécula antigênica, agente fotossensibilizante e citocina, produto, e, kit - Google Patents
métodos para expressar uma molécula antigênica ou uma parte da mesma e gerar uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e molécula antigênica, molécula antigênica, agente fotossensibilizante e citocina, produto, e, kitInfo
- Publication number
- BR112017003486A2 BR112017003486A2 BR112017003486A BR112017003486A BR112017003486A2 BR 112017003486 A2 BR112017003486 A2 BR 112017003486A2 BR 112017003486 A BR112017003486 A BR 112017003486A BR 112017003486 A BR112017003486 A BR 112017003486A BR 112017003486 A2 BR112017003486 A2 BR 112017003486A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigenic molecule
- cell population
- cell
- cytokine
- expressing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 230000000890 antigenic effect Effects 0.000 title abstract 4
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003504 photosensitizing agent Substances 0.000 title 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201415247A GB201415247D0 (en) | 2014-08-28 | 2014-08-28 | Compound and method |
| GB201420773A GB201420773D0 (en) | 2014-11-21 | 2014-11-21 | Compound and method |
| PCT/EP2015/069794 WO2016030529A1 (en) | 2014-08-28 | 2015-08-28 | Compound and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017003486A2 true BR112017003486A2 (pt) | 2018-01-16 |
Family
ID=54065872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017003486A BR112017003486A2 (pt) | 2014-08-28 | 2015-08-28 | métodos para expressar uma molécula antigênica ou uma parte da mesma e gerar uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e molécula antigênica, molécula antigênica, agente fotossensibilizante e citocina, produto, e, kit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10537639B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3185901B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2017526371A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102678732B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108136016A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015308345B9 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017003486A2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ729408A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016030529A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912607B (zh) * | 2018-12-11 | 2021-01-22 | 南华大学 | 一类卟啉-白杨素复合物及其抗肿瘤活性 |
| JP7288951B2 (ja) | 2019-02-19 | 2023-06-08 | 大塚電子株式会社 | 光線力学的療法条件パラメータの決定方法および光線力学的療法装置 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| CA2430087C (en) | 2000-11-29 | 2016-06-28 | Pci Biotech As | Photochemical internalization for delivery of molecules into the cytosol |
| AU3069302A (en) | 2000-12-13 | 2002-06-24 | Immunex Corp | Method for generating immortal dendritic cell lines |
| GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
| AU2004289368B2 (en) | 2003-11-12 | 2010-08-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Custom vectors for treating and preventing pancreatic cancer |
| WO2005097976A1 (ja) | 2004-04-06 | 2005-10-20 | Ehime University | 抗原パルスして得られた樹状細胞 |
| WO2005100547A1 (ja) * | 2004-04-06 | 2005-10-27 | Techno Network Shikoku Co., Ltd. | 抗原パルスして得られた樹状細胞 |
| CN102099054A (zh) * | 2008-06-06 | 2011-06-15 | 贝勒研究院 | 呼吸道合胞病毒呈递树突细胞致耐受性 |
| EP2456787A4 (en) | 2009-07-24 | 2013-01-30 | Univ Leland Stanford Junior | CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE |
| GB201208548D0 (en) * | 2012-05-15 | 2012-06-27 | Pci Biotech As | Compound and method |
| WO2014139597A1 (en) | 2013-03-15 | 2014-09-18 | Pci Biotech As | Method |
| WO2015028575A1 (en) | 2013-08-28 | 2015-03-05 | Pci Biotech As | Immunisation method by photochemical internalisation |
| AU2014314149B2 (en) | 2013-08-28 | 2019-12-19 | Pci Biotech As | Compound and method for vaccination and immunisation |
| AU2014390262B2 (en) | 2014-04-11 | 2020-11-26 | Pci Biotech As | Method of treating melanoma |
-
2015
- 2015-08-28 CN CN201580055883.9A patent/CN108136016A/zh active Pending
- 2015-08-28 KR KR1020177008280A patent/KR102678732B1/ko active Active
- 2015-08-28 US US15/506,453 patent/US10537639B2/en active Active
- 2015-08-28 JP JP2017511702A patent/JP2017526371A/ja active Pending
- 2015-08-28 BR BR112017003486A patent/BR112017003486A2/pt active Search and Examination
- 2015-08-28 AU AU2015308345A patent/AU2015308345B9/en active Active
- 2015-08-28 WO PCT/EP2015/069794 patent/WO2016030529A1/en not_active Ceased
- 2015-08-28 EP EP15760426.5A patent/EP3185901B1/en active Active
- 2015-08-28 NZ NZ729408A patent/NZ729408A/en unknown
-
2020
- 2020-07-17 JP JP2020123157A patent/JP7079819B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3185901A1 (en) | 2017-07-05 |
| JP2017526371A (ja) | 2017-09-14 |
| EP3185901C0 (en) | 2023-10-04 |
| US10537639B2 (en) | 2020-01-21 |
| CN108136016A (zh) | 2018-06-08 |
| JP2020182486A (ja) | 2020-11-12 |
| AU2015308345B2 (en) | 2020-12-10 |
| JP7079819B2 (ja) | 2022-06-02 |
| AU2015308345A1 (en) | 2017-03-16 |
| NZ729408A (en) | 2021-12-24 |
| US20170252441A1 (en) | 2017-09-07 |
| AU2015308345B9 (en) | 2020-12-24 |
| CA2959207A1 (en) | 2016-03-03 |
| KR20170047336A (ko) | 2017-05-04 |
| EP3185901B1 (en) | 2023-10-04 |
| KR102678732B1 (ko) | 2024-06-25 |
| WO2016030529A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| ECSP19010079A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| MX2018009917A (es) | Vacuna contra el virus del zika. | |
| MX2017014082A (es) | Nuevas proteinas especificas para cd137. | |
| BR112016029906A2 (pt) | compostos excipientes redutores de viscosidade para formulações proteicas | |
| UY37098A (es) | Moduladores de ror-gamma | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| BR112017018948A2 (pt) | método | |
| AR112069A1 (es) | Inmunoglobulinas que fijan aggrecan | |
| BR112018013227A2 (pt) | ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição? | |
| BR112018073007A2 (pt) | terapia de combinação inicial:reforço | |
| MX2019014027A (es) | Uso de glutamina sintetasa para tratar hiperamonemia. | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| BR112016022787A2 (pt) | método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica | |
| BR112014020025A2 (pt) | vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| BR112017003486A2 (pt) | métodos para expressar uma molécula antigênica ou uma parte da mesma e gerar uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e molécula antigênica, molécula antigênica, agente fotossensibilizante e citocina, produto, e, kit | |
| EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| CL2018002848A1 (es) | Formulaciones liquidas de fosfoplatino | |
| CL2016000397A1 (es) | Tratamiento contra el cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 41/00 (2006.01), A61K 47/00 (2006.01), C12N 5 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |